San Francisco Reports First Flu-Related Fatality of the Season

San Francisco health authorities announced Thursday that the city has recorded its first influenza-related fatality of the 2026-27 flu season. The San Francisco Department of Public Health (SFDPH) identified the deceased as an adult but did not release additional identifying details.

Dr. Susan Philip, San Francisco’s health officer, emphasized the importance of vigilance as respiratory viruses continue to circulate. “This sad news reminds us that respiratory viruses such as flu and COVID should be taken very seriously, especially for people who are at higher risk of getting sick,” Philip said in a public statement. She added that getting vaccinated is crucial for ensuring residents can safely enjoy upcoming fall celebrations.

Data released by the California Department of Public Health indicates that 26 people statewide have died from influenza this season. It remains unclear whether the San Francisco case is included in that figure. These fatalities have occurred earlier than typical, as the CDC’s official tabulation suggests the flu season is not scheduled to begin for another two weeks. Currently, national respiratory virus activity is classified as “very low,” though cases historically rise during the fall and winter months.

Health officials continue to urge individuals to receive their flu shots before the end of October. The vaccine is widely available at pharmacies and medical offices, often at no cost to those with insurance coverage. While all individuals over six months old are eligible for standard vaccines, adults aged 65 and older may qualify for higher-dose versions designed to boost immune response.

The SFDPH also encouraged the public to remain current with COVID-19 and RSV vaccinations according to state guidelines. Updated 2026-27 COVID vaccines are recommended for children aged 6 to 23 months, adults aged 65 and older, individuals aged 2 to 18 with risk factors or no prior vaccination history, and those aged 19 to 64 with underlying health conditions. Pregnant individuals, those planning pregnancy, and close contacts of high-risk persons, including healthcare workers, are also prioritized.

For RSV, the vaccine is advised for previously unvaccinated adults aged 75 and older, as well as those aged 50 to 74 with risk factors. Pregnant people between 32 and 36 weeks of gestation who have not been vaccinated are also eligible. Additionally, infants under 8 months whose mothers did not receive the vaccine during pregnancy, along with high-risk children aged 8 to 19 months, can receive an injectable monoclonal antibody to protect against RSV.